secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001493152-24-009950
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics FY2023 revenue drops 80% to $6.8M; net loss widens to $35.3M
---------------------------------------------------------------------------

- Revenue of $6.8M, down from $34.2M in 2022, driven by decline in COVID-19 test demand.
- Net loss of $35.3M ($1.20 per diluted share) vs. $14.2M ($0.45) in prior year.
- Operating loss of $42.7M; adjusted EBITDA loss of $33.0M.
- Submitted EUA to FDA for Co-Dx PCR Pro platform and COVID-19 test in December 2023.
- Appointed Ivory Chang as Chief Regulatory Affairs Officer; secured $12.6M in grants for TB, respiratory, HPV tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/0001493152-24-009950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer